Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple

Pediatric Research

Volumn 62, Issue 1, 2007, Pages 111-115

  Polack, Fernando P ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; MEASLES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ABDOMINAL PAIN; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ATYPICAL MEASLES; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG ERUPTION; DRUG FEVER; EOSINOPHILIA; EPIDEMIC; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LIVER DYSFUNCTION; MEASLES; MEASLES VIRUS; NONHUMAN; PARAMYXOVIRUS; PATHOGENESIS; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SEROCONVERSION; VIRUS INFECTION; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; CHILD; HUMANS; MEASLES; MEASLES VACCINE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 34250848281     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3180686ce0     Document Type: Review

References (50)

1. Griffin D 2001 Measles Virus. In: Knipe DM, Howley PM (eds) Fields Virology. Lippincott/The Williams and Wilkins Co, Philadelphia, PA, pp 1401-1443
2. Collins PL, Chanock RM, Murphy BR 2001 Respiratory Syncytial Virus. In: Knipe, DM, Howley PM (eds) Fields Virology. Lippincott/ The Williams and Wilkins Co, Philadelphia, PA, pp 1443-1486
3. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH 1969 Respiratory syncytial virus disease in infant despite prior administration on antigenic inactivated vaccine. Am J Epidemiol 89:422-434
4. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH 1969 Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89:449-463
5. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G 1969 Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccine; an aqueous trivalent parainfluenza virus vaccine and an alumprecipitated respiratory syncytial virus vaccine. Am J Epidemiol 89:435-448
6. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE 1969 An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89:405-421
7. Carter CH, Conway TJ, Cornfeld D, Iezzoni DG, Kempe CH, Moscovici C, Rauh LW, Vignec AJ, Warren J 1962 Serologic response of children to inactivated measles vaccine. JAMA 179:848-853
8. Guinnee VF, Henderson DA, Casey HL, Wingo ST, Ruthiq DW, Cockburn TA, Vinson TO, Calafiore DC, Wilkenstein W Jr, Karzon DT, Rathbun ML, Alexander ER, Peterson DR 1966 Cooperative measles vaccine field trial I. Clinical efficacy. Pediatrics 37:649-665
9. Fulginiti VA, Eller JJ, Downie AW, Kempe CH 1967 Altered reactivity to measles virus: Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075-1080
10. Martin DB, Weiner LB, Nieburg PI, Blair DC 1979 Atypical measles in adolescents and young adults. Ann Intern Med 90:877-881
11. Young LW, Smith DI, Glasgow LA 1970 Pneumonia of atypical measles. Residual nodular lesions. Am J Roentgenol Radium Ther Nucl Med 110:439-448
12. Rauh LW, Schmidt R 1965 Measles immunization with killed virus vaccine. Am J Dis Child 109:232-237
13. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y 1998 Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527-532
14. Albrecht P, Ennis FA, Saltzman EJ, Krugman S 1977 Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failure. J Pediatr 91:715-718
15. Glezen WP, Taber LH, Frank AL, Kasel JA 1986 Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:543-546
16. Bellanti JA 1971 Biologic significance of the secretory Û. A immunoglobulins. Pediatrics 48:715-729
17. Buser F 1967 Side reaction to measles vaccination suggesting the Arthus phenomenon. N Engl J Med 277:250-251
18. Lennon RG, Isacson P, Rosales T, Elsea WR, Karzon DT, Winkelstein W Jr 1967 Skin tests with measles and poliomyelitis vaccines in recipients of inactivated measles virus vaccine. Delayed Dermal Hypersensitivity JAMA 200:275-280.
19. Fulginiti VA, Arthur JH, Pearlman DS, Kempe CH 1968 Altered reactivity to measles virus: Local reactions following attenuated measles virus immunization in children who previously received a combination of inactivated and attenuated vaccines. Am J Dis Child 115:671-676
20. Scott TF, Bonnanno DE 1967 Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine. N Engl J Med 277:248-250
21. Norrby E, Enders-Ruckle G, Ter Meulen V 1975 Difference in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus. J Infect Dis 132:262-269
22. Norrby E, Gollmar Y 1975 Identification of measles virus-specific hemolysisinhibiting antibodies separate from hemagglutination-inhibiting antibodies. Infect Immun 11:231-239
23. Merz DC, Scheid A, Choppin PW 1980 Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J Exp Med 151:275-288
24. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ 1996 Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70:2852-2860
25. De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, Neijens HJ, Andeweg AC, Osterhaus AD 2002 Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent infection. J Virol 76:11561-11569
26. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, Murphy BR 1994 Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68:5321-5325
27. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG 1993 Priming immunization determines T-helper cytokine mRNA wxpression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151:2032-2040
28. Polack FP, Auwaerter PG, Lee SH, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE 1999 Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 5:629-634
29. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE 2003 A role for non-protective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 9:1209-1213
30. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA 2002 A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196:859-865
31. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC 3rd, Sotnikov AV, Murphy BR 1992 Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66:7444-7451
32. Kim HW, Keikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH 1976 Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 10:75-78
33. Krause PJ, Cherry JD, Carney JM, Naiditch MJ, O'Connor K 1980 Measles-specific lymphocyte reactivity and serum antibody in subjects with different measles histories. Am J Dis Child 134:567-571
34. Polack FP, Hoffman SJ, Moss WJ, Griffin DE 2002 Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles. J Infect Dis 185:13-19
35. Hussell T, Baldwin CJ, O'Garra A, Openshaw PJ 1997 CD8+ T-Cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 27:3341-3349
36. Srikiatkhachorn A, Braciale TJ 1997 Virus-specific CD8+ lymphocytes downregulate T-helper cell Type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 186:421-432
37. Tang YW, Graham BS 1994 Anti-interleukin-4 treatment after immunization modulates cytokine expression, reduces illness and increases cytotoxic T-lymphocyte activity in mice challenged with RSV. J Clin Invest 94:1953-1958
38. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ 2006 A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12:905-907
39. Srikiatkhachorn A, Chang W, Braciale TJ 1999 Induction of the Th 1 and Th 2 responses by respiratory syncytial virus attachment glycoprotein is epitope ad MHC independent. J Virol 73:6590-6597
40. Prince GA, Curtis SJ, Yim KC, Porter DD 2001 Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82:2881-2888
41. Tang YW, Graham BS 1994 Anti-interleukin-4 treatment after immunization modulates cytokine expression, reduces illness and increases cytotoxic T-lymphocyte activity in mice challenged with RSV. J Clin Invest 94:1953-1958
42. Polack FP, Lee SH, Permar S, Manyara E, Nousari HG, Jeng Y, Mustafa F, Valsamakis A, Adams RJ, Robinson HL, Griffin DE 2000 Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 6:776-781
43. Johnson TR, Varga SM, Braciale TJ, Graham BS 2004 Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol 78:8753-8760
44. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR 2005 The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci USA 102:8996-9001
45. Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, Polack FP 2006 The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J Virol 80:5854-5861
46. Murphy BR, Walsh EE 1988 Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusioninhibiting activity. J Clin Microbiol 26:1595-1597
47. Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR 1992 Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484
48. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA 1990 Enhanced pulmonary histopathology is observed in cotton rats immunized with formalininactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8:497-502
49. Murphy BR, Sotnikov A, Paradiso PR, Hildreth SW, Jenson AB, Baggs RB, Lawrence L, Zubak JJ, Chanock RM, Beeler JA 1989 Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7:533-540
50. Melendi GA, Hoffman SJ, Karron RA, Irusta PM, Laham FR, Humbles A, Schofield B, Pan CH, Rabold R, Thumar B, Thumar A, Gerard NP, Mitzner W, Barnum SR, Gerard C, Kleeberger SR, Polack FP 2007 C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. J Virol 81:991-999